Onconetix(US:ONCO) Globenewswire·2026-02-12 13:00Core Viewpoint - Onconetix, Inc. is acquiring Realbotix LLC in an all-stock transaction, aiming to enhance shareholder value through the integration of Realbotix's advanced humanoid robotics technology [1][4]. Company Overview - Onconetix, Inc. is a biotechnology company focused on oncology solutions, including the Proclarix® diagnostic test for prostate cancer [8]. - Realbotix LLC specializes in AI-powered humanoid robotics, designed for customer-facing roles across various industries such as healthcare, education, hospitality, and entertainment [2][9]. Transaction Details - The share exchange agreement allows Onconetix to acquire 100% of Realbotix's equity interests, with Realbotix Parent expected to hold between 75% and 90% of the combined company's shares post-transaction [4][5]. - The transaction has been unanimously approved by the boards of both companies and is subject to customary closing conditions, including shareholder approval and regulatory clearances [5]. Technological Advancements - Realbotix is recognized for its patented technologies that enable lifelike expressions and social interactions, allowing its robots to operate autonomously without human teleoperation [3]. - The robots are equipped with advanced vision systems capable of interpreting emotional visual cues and situations, enhancing their functionality in public venues [3]. Strategic Importance - The merger is viewed as a strategic move to unlock significant value for shareholders and to position the combined entity for future growth in the humanoid robotics market [4]. - Andrew J. Oakley, Chairman of Onconetix, expressed excitement about the potential to change the company's strategic direction through this acquisition [3].